Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 10/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133902 | 1.00 | ADRB3 (0.41) | ADRB3ADRB1USP2MAPTCA12 | |
| SCHEMBL6134327 | 0.91 | ADRB3 (0.44) | ADRB3ADRB1 | |
| SCHEMBL6134323 | 0.91 | ADRB3 (0.44) | ADRB3ADRB1 | |
| SCHEMBL6134328 | 0.91 | ADRB3 (0.44) | ADRB3ADRB1 | |
| SCHEMBL6135470 | 0.88 | ADRB3 (0.45) | ADRB3ADRB1 | |
| SCHEMBL6135475 | 0.88 | ADRB3 (0.45) | ADRB3ADRB1 | |
| SCHEMBL6133908 | 0.84 | ADRB3 (0.43) | ADRB3ADRB1 | |
| SCHEMBL6133641 | 0.84 | ADRB3 (0.41) | ADRB3ADRB1 | |
| SCHEMBL6133638 | 0.84 | ADRB3 (0.41) | ADRB3ADRB1 | |
| SCHEMBL6134371 | 0.82 | ADRB3 (0.49) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ASTELLAS PHARMA INC. (JP) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090669-A1 | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ADRB3 3/4885ADRB1 2/4885USP2 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.